San Diego, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced today that Punit Dhillon, CEO, Skye Bioscience will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference on Tuesday, March 09, 2021. Mr. Dhillon will also be available for virtual one-on-one meetings during the conference.

Read this article:
Skye Bioscience to Present at H.C. Wainwright Global Life Sciences Conference

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh